{Reference Type}: Journal Article
{Title}: Characterization of ascending dose canine telemetry model supports its use in E14/S7B QT integrated risk assessments.
{Author}: Chaves AA;Ferraro JW;Yu J;Moye MJ;Yee KL;Li F;Steve DL;Lengel DJ;Regan CP;
{Journal}: J Pharmacol Toxicol Methods
{Volume}: 128
{Issue}: 0
{Year}: 2024 Jun 6
{Factor}: 2.285
{DOI}: 10.1016/j.vascn.2024.107525
{Abstract}: <B>BACKGROUND: </B>Nonclinical evaluation of the cardiovascular effects of novel chemical or biological entities (NCE, NBEs) is crucial for supporting first-in-human clinical trials. One important aspect of these evaluations is the assessment of potential QT/QTc prolongation risk, as drug-induced QT prolongation can have catastrophic effects. The recent publication of E14/S7B Q&As allows for the situational incorporation of nonclinical QTc data as part of an integrated risk assessment for a Thorough QT (TQT) waiver application provided certain best practice criteria are met. Recent publications provided detailed characterization of nonclinical QTc telemetry data collected from the commonly used Latin square study design.<BR><B>METHODS: </B>To understand whether data from alternate telemetry study designs were sufficient to serve as part of the E14/S7B integrated risk assessment, we report the performance and translational sensitivity to identify clinical risk of QTc prolongation risk for an ascending dose telemetry design.<BR><B>RESULTS: </B>The data demonstrated low variability in QTci interval within animals from day to day, indicating a well-controlled study environment and limited concern for uncontrolled effects across dosing days. Historical study variances of the ascending dose design with n = 4 subjects, measured by least significant difference (LSD) and root mean square error (RMSE) values, were low enough to detect a + 10 ms QTci interval change, and the median minimum detectable difference (MDD) for QTci interval changes was <10 ms. Furthermore, concentration-QTci (C-QTci) assessments to determine +10 ms QTci increases for known hERG inhibitors were comparable to clinical CC values listed in the E14/S7B training materials, supporting the use of the ascending dose design in an E14/S7B integrated risk assessment.<BR><B>CONCLUSIONS: </B>These findings suggest that the ascending dose design can be a valuable tool in nonclinical evaluation of QT/QTc prolongation risk and the support of TQT waiver applications.